Peptide Therapeutics Market: Regional Analysis and Market Segmentation

1
Peptide Therapeutics Market by Manufacturers,
Regions, Type and Application Forecast to 2032
2

• Industry Insights

• Increasing demand for personalized and targeted
  treatment options pushed by the growing burden of
  chronic diseases such as diabetes, cancer, and
  cardiovascular disorders will stimulate industry
  revenue streams over the next ten years.
  According to WHO, diabetes affects around 422
  million people worldwide and claims the lives of
  1.5 million people each year.
• Peptide therapeutics offer advantages like high
  specificity, low toxicity, and excellent
  biocompatibility, making them an attractive
  choice for drug development. Advancements in
  peptide synthesis technologies and drug delivery
  systems have improved the stability,
  bioavailability, and half-life of peptide drugs,
  further propelling their adoption.
• Moreover, ongoing RD activities, in line with
  increasing collaborations between academic
  institutions and pharmaceutical companies, will
  fuel the discovery of novel peptide-based
  therapies, driving market growth.

3

• Regarding the type, the generic peptide
  therapeutics industry will register significant
  gains through 2032. The expiration of patents for
  original peptide drugs has opened the market for
  generic versions, offering cost-effective
  alternatives.
• The increasing burden of chronic diseases has
  created a need for affordable treatment options,
  further stimulating the demand for generic
  peptide therapeutics.
• Besides, regulatory initiatives promoting the use
  of generic drugs have encouraged their adoption
  in healthcare systems worldwide, which will help
  augment segment gains over the coming years.
• With respect to application, the peptide
  therapeutics market size from the cancer segment
  will grow substantially over 2023-2032. The
  demand for peptide therapeutics in cancer
  applications is increasing due to their potential
  for targeted and personalized treatment. Peptides
  can specifically target cancer cells while
  sparing healthy cells, reducing side effects.
  Additionally, peptide-based immunotherapies, such
  as immune checkpoint inhibitors, have shown
  promising results in boosting the body's immune
  response against cancer cells.

4

• Regional Analysis

• Regionally, the Asia Pacific peptide therapeutics
  market will exhibit an appreciable growth rate
  between 2023 and 2032. The increasing prevalence
  of chronic diseases, such as cancer, diabetes,
  and cardiovascular disorders, has created a
  significant need for effective treatment options.

• Competitive Analysis

• The key players in peptide therapeutics market
  are Pfizer, Inc., Amgen, Inc., Bachem Holding AG,
  Eli Lilly and Company, Sanofi, AstraZeneca plc,
  AbbVie, GlaxoSmithKline plc, Baush Health, and
  Lonza Inc. These companies are implementing
  several strategies such as collaborations,
  acquisitions, partnerships, mergers, and product
  launches, etc. to maintain a competitive edge in
  the industry.

5
Peptide Therapeutics Market _at_ https//www.gminsigh
ts.com/industry-analysis/peptide-therapeutics-mark
et
Request for sample of this research report _at_
https//www.gminsights.com/request-sample/detail/5
635
Request for customization _at_ https//www.gminsights
.com/roc/5635
6
Stay In Touch Social Media
7
THANK YOU
www.gminsights.com